BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

903 related articles for article (PubMed ID: 16023184)

  • 1. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear.
    Monsonego J; Bohbot JM; Pollini G; Krawec C; Vincent C; Merignargues I; Haroun F; Sednaoui P; Monfort L; Dachez R; Syrjänen K
    Gynecol Oncol; 2005 Oct; 99(1):160-8. PubMed ID: 16023184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linear array genotyping and hybrid capture II assay in detecting human papillomavirus genotypes in women referred for colposcopy due to abnormal Papanicolaou smear.
    Monsonego J; Pollini G; Evrard MJ; Sednaoui P; Monfort L; Quinzat D; Dachez R; Syrjänen K
    Int J STD AIDS; 2008 Jun; 19(6):385-92. PubMed ID: 18595876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
    Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
    Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear.
    De Francesco MA; Gargiulo F; Schreiber C; Ciravolo G; Salinaro F; Manca N
    J Virol Methods; 2008 Jan; 147(1):10-7. PubMed ID: 17854914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group.
    Lytwyn A; Sellors JW; Mahony JB; Daya D; Chapman W; Ellis N; Roth P; Lorincz AT; Gafni A
    CMAJ; 2000 Sep; 163(6):701-7. PubMed ID: 11022584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid-based cytology--new possibilities in the diagnosis of cervical lesions.
    Juric D; Mahovlić V; Rajhvajn S; Ovanin-Rakić A; Skopljanac-Macina L; Barisić A; Projić IS; Babić D; Susa M; Corusić A; Oresković S
    Coll Antropol; 2010 Mar; 34(1):19-24. PubMed ID: 20432728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P16(INK4a) immunocytochemistry in liquid-based cytology samples in equivocal Pap smears: added value in management of women with equivocal Pap smear.
    Monsonego J; Pollini G; Evrard MJ; Sednaoui P; Monfort L; Quinzat D; Dachez R; Syrjänen K
    Acta Cytol; 2007; 51(5):755-66. PubMed ID: 17910346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing atypical squamous cells of undetermined significance in Papanicolaou smears.
    Morin C; Bairati I; Bouchard C; Fortier M; Roy M; Moore L; Meisels A
    J Reprod Med; 2001 Sep; 46(9):799-805. PubMed ID: 11584480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia.
    Monsonego J; Pintos J; Semaille C; Beumont M; Dachez R; Zerat L; Bianchi A; Franco E
    Int J Gynecol Cancer; 2006; 16(2):591-8. PubMed ID: 16681731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: cross-sectional data from a triage population.
    Leeman A; Del Pino M; Molijn A; Rodriguez A; Torné A; de Koning M; Ordi J; van Kemenade F; Jenkins D; Quint W
    BJOG; 2017 Aug; 124(9):1356-1363. PubMed ID: 28391609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of AMPLICOR and Hybrid Capture II assays for high risk HPV detection in normal and abnormal liquid-based cytology: use of INNO-LiPA Genotyping assay to screen the discordant results.
    Mo LZ; Monnier-Benoit S; Kantelip B; Petitjean A; Riethmuller D; Prétet JL; Mougin C
    J Clin Virol; 2008 Feb; 41(2):104-10. PubMed ID: 18036888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico.
    Salmerón J; Lazcano-Ponce E; Lorincz A; Hernández M; Hernández P; Leyva A; Uribe M; Manzanares H; Antunez A; Carmona E; Ronnett BM; Sherman ME; Bishai D; Ferris D; Flores Y; Yunes E; Shah KV
    Cancer Causes Control; 2003 Aug; 14(6):505-12. PubMed ID: 12948281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary and Triage Cervical Screening Diagnostic Value of Methods for the Detection of Cervical Dysplasia.
    Njue JK; Muturi M; Kamau L; Lwembe R
    Biomed Res Int; 2022; 2022():1930102. PubMed ID: 36164451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Tay SK; Lin LE; Goh RC
    Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of human papillomavirus testing by hybrid capture in the triage of women with repeated abnormal pap smears before colposcopy referral.
    Fait G; Kupferminc MJ; Daniel Y; Geva E; Ron IG; Lessing JB; Bar-Am A
    Gynecol Oncol; 2000 Nov; 79(2):177-80. PubMed ID: 11063640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.